F-627: Phase II started

Generon began an open-label, international Phase II trial to compare F-627 vs. Neulasta pegfilgrastim in about 200 breast cancer patients receiving myelotoxic chemotherapy. Amgen Inc. (NASDAQ:AMGN, ...